Description

Tempus AI’s AstraZeneca, BioNTech & Merck Deals — Pharma Demand Keeps Building

Tempus AI reported total revenue growth of 22% year-over-year in the second quarter of 2026, reaching $382.5 million, marking the first quarter with full integration of Ambry Genetics in the results. The Diagnostics segment accounted for $289.3 million of revenue, up 20% year-over-year, despite slower growth in hereditary cancer testing balanced by accelerated growth in comprehensive genomic profiling (CGP). Hereditary testing revenues increased by 5%, while the Data and Applications segment grew 28% to $93.2 million, driven by a 36% rise in data licensing and modeling business insights. Significant milestones included FDA approval for their tumor-only xT CDx, enabling unified pricing under the Advanced Diagnostic Laboratory Test (ADLT) framework, which is expected to increase average selling prices (ASP) by about $200 per test and add roughly $85 million in annual revenue beginning in 2027.